...
首页> 外文期刊>Japanese Journal of Pharmacology >Pharmacodynamic and Pharmacokinetic Studies on Prizidilol and Nipradilol (K-351), Antihypertensive Drugs with Combined Vasodilator and β-Adrenoceptor Blocking Actions, in Rabbits
【24h】

Pharmacodynamic and Pharmacokinetic Studies on Prizidilol and Nipradilol (K-351), Antihypertensive Drugs with Combined Vasodilator and β-Adrenoceptor Blocking Actions, in Rabbits

机译:哌齐地洛尔和尼帕地洛尔(K-351),降压药与血管扩张剂和β-肾上腺素受体阻断剂的联合作用,在家中的药效和药代动力学研究

获取原文
           

摘要

References(18) Cited-By(6) Effects of prizidilol and nipradilol (K-351), β-adrenoceptor antagonists with vasodilator action, on blood pressure and heart rate were studied in normotensive conscious rabbits after i.v. administration. In addition, we investigated relationships between plasma drug concentrations and β-adrenoceptor blocking activity as estimated by the inhibition of isoproterenol-induced tachycardia and vasodilator activity as assessed by the inhibition of pressor response to angiotensin II (ANG II). Prizidilol (4 mg/kg) produced a significant and sustained fall in blood pressure and a slight increase in heart rate, while hydralazine (2 mg/kg) caused the same degree of hypotension and a marked tachycardia. Nipradilol (1 mg/kg) caused a significant reduction of resting heart rate, but had no significant effect on blood pressure. Propranolol (1 mg/kg) did not affect resting blood pressure and heart rate. Hypertensive response to ANG II was significantly attenuated only by hydralazine. Isoproterenol -induced tachycardia was significantly suppressed by prizidilol, nipradilol and propranolol. Good correlations were observed between β-adrenoceptor blocking activity and plasma drug concentrations. These data suggest that prizidilol has an advantage over hydralazine to induce less tachycardia, but still may cause a certain degree of increase in heart rate. Nipradilol has a more potent β-adrenoceptor blocking action than propranolol, while its vasodilator action is not obvious, at least in rabbits. Plasma concentrations of prizidilol and nipradilol are good indicators for β-adrenoceptor blocking activity, but not for vasodilator activity.
机译:参考文献(18)(6)研究了血压正常的家兔静脉内麻醉后对具有血管舒张作用的β-肾上腺素能受体拮抗剂哌齐地洛和尼帕地洛(K-351)的影响。行政。此外,我们研究了血浆药物浓度与β-肾上腺素受体阻断活性之间的关系,后者通过抑制异丙肾上腺素引起的心动过速而估计,而血管舒张活性则通过抑制对血管紧张素II(ANG II)的升压反应来评估。哌齐洛尔(4 mg / kg)导致血压持续显着下降,心率略有增加,而肼屈嗪(2 mg / kg)引起相同程度的低血压和明显的心动过速。 Nipradilol(1 mg / kg)导致静息心率显着降低,但对血压没有明显影响。普萘洛尔(1 mg / kg)不会影响静息血压和心率。仅通过肼屈嗪可显着减轻对ANG II的高血压反应。异丙肾上腺素,尼普地洛和普萘洛尔可明显抑制异丙肾上腺素引起的心动过速。在β-肾上腺素受体阻断活性和血浆药物浓度之间观察到良好的相关性。这些数据表明,吡嗪醇比肼苯哒嗪具有优势,可诱导较少的心动过速,但仍可能导致一定程度的心率增加。尼普地洛比普萘洛尔具有更强的β-肾上腺素受体阻断作用,而其血管舒张作用并不明显,至少在兔子中是如此。血浆中的哌齐洛尔和尼泊地洛尔浓度是β-肾上腺素受体阻断活性的良好指标,但不是血管扩张剂活性的良好指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号